Latest news with #Clarivate
Yahoo
19-05-2025
- Business
- Yahoo
Clarivate Unveils AI-Powered Tool for Trademark Risk Assessment
On May 19, Clarivate Plc (NYSE:CLVT) launched RiskMark, an AI-driven trademark risk evaluation tool combining CompuMark trademark data and Darts-ip litigation records. Using 172.5 million trademark records across 188 jurisdictions and 5 million legal cases, RiskMark employs generative and predictive AI to assess similarity risks, aiding trademark professionals in strategic decision-making and argument drafting. A closeup shot of a laboratory technician handling a medical device used for fertility treatments. François Neuville, Senior Vice President at Clarivate, stated: "Trademark professionals are under pressure to make critical decisions when creating and protecting brands. Beyond the administrative elements, it is essential to be able to craft arguments for trademark examiners or for litigation based on precedent and following clear legal principles. Our new tool will enable trademark professionals to do this with speed, ease, and confidence. Thanks to our gold-standard data we can empower IP professionals with trustworthy AI-driven insights to assess risk and accelerate drafting, positioning them for both immediate and long-term success." Clarivate is a global leader in transformative intelligence, providing data-driven insights, analytics, workflow solutions, and expert services across Academia & Government, Intellectual Property, and Life Sciences & Healthcare. While we acknowledge the potential of Clarivate Plc (NYSE:CLVT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CLVT and that has 100x upside potential, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None.
Yahoo
19-05-2025
- Business
- Yahoo
Clarivate Launches AI-based RiskMark to Accelerate Trademark Conflict Assessments
New AI-based solution empowers trademark professionals to evaluate trademark risk and generate evidence-backed arguments with speed, ease, and confidence LONDON, May 19, 2025 /CNW/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of RiskMark, an AI-powered solution combining global CompuMark trademark data and Darts-ip litigation data to evaluate trademark risk. Leveraging 172.5 million trademark records spanning 188 jurisdictions and over 5 million global court and administrative records, RiskMark combines generative and predictive AI to transform the process of assessing similarity risk based on relevant evidence. This enables trademark professionals to make strategic decisions and craft arguments with greater speed and confidence. The solution generates near-instant results on visual, phonetic, connotation, and goods and services relatedness to accelerate informed decision-making. RiskMark also assists customers in argument drafting. With AI-generated arguments, RiskMark provides a strong starting point for drafting opposition responses grounded in legal principles and can help identify insights into potential arguments from opponents. François Neuville, Senior Vice President, Brand IP, Clarivate, said: "Trademark professionals are under pressure to make critical decisions when creating and protecting brands. Beyond the administrative elements, it is essential to be able to craft arguments for trademark examiners or for litigation based on precedent and following clear legal principles. Our new tool will enable trademark professionals to do this with speed, ease, and confidence. Thanks to our gold-standard data we can empower IP professionals with trustworthy AI-driven insights to assess risk and accelerate drafting, positioning them for both immediate and long-term success." To learn more, please visit About ClarivateClarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit Media contact:Sofia Nogués, Sr. External Communications Managernewsroom@ View original content to download multimedia: SOURCE Clarivate Plc View original content to download multimedia: Sign in to access your portfolio
Yahoo
19-05-2025
- Business
- Yahoo
Clarivate Launches AI-based RiskMark to Accelerate Trademark Conflict Assessments
New AI-based solution empowers trademark professionals to evaluate trademark risk and generate evidence-backed arguments with speed, ease, and confidence LONDON, May 19, 2025 /CNW/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of RiskMark, an AI-powered solution combining global CompuMark trademark data and Darts-ip litigation data to evaluate trademark risk. Leveraging 172.5 million trademark records spanning 188 jurisdictions and over 5 million global court and administrative records, RiskMark combines generative and predictive AI to transform the process of assessing similarity risk based on relevant evidence. This enables trademark professionals to make strategic decisions and craft arguments with greater speed and confidence. The solution generates near-instant results on visual, phonetic, connotation, and goods and services relatedness to accelerate informed decision-making. RiskMark also assists customers in argument drafting. With AI-generated arguments, RiskMark provides a strong starting point for drafting opposition responses grounded in legal principles and can help identify insights into potential arguments from opponents. François Neuville, Senior Vice President, Brand IP, Clarivate, said: "Trademark professionals are under pressure to make critical decisions when creating and protecting brands. Beyond the administrative elements, it is essential to be able to craft arguments for trademark examiners or for litigation based on precedent and following clear legal principles. Our new tool will enable trademark professionals to do this with speed, ease, and confidence. Thanks to our gold-standard data we can empower IP professionals with trustworthy AI-driven insights to assess risk and accelerate drafting, positioning them for both immediate and long-term success." To learn more, please visit About ClarivateClarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit Media contact:Sofia Nogués, Sr. External Communications Managernewsroom@ View original content to download multimedia: SOURCE Clarivate Plc View original content to download multimedia: Sign in to access your portfolio
Time of India
16-05-2025
- Business
- Time of India
At nearly 5.4 lakh, India ranks third in trademark filings
Representative photo NEW DELHI: Reflecting strong business confidence, India ranked third globally in trademark filings, with nearly 5.4 lakh new applications in 2024, narrowing the gap with the US, the second-biggest filer with a little under 5.7 lakh applications. China maintained its lead with 68 lakh filings, despite a steady three-year decline in activity. According to data shared with TOI by Clarivate, a global provider of transformative intelligence, India witnessed 9.3% growth. The strong growth suggests an increasing awareness about the importance of creating brands and the value of intellectual property among local Indian businesses. China tops with 68 lakh, US stood 2nd It also indicates strong local commercial confidence and investment as businesses and entrepreneurs seek to take advantage of increasing opportunities and consumer demand for new products and services in the Indian market, Robert Reading, head of IP content strategy at Clarivate, told TOI. Over the past decade, the USPTO averaged 5% annual growth in trademark filing volume, while the Indian Trademark Office saw average annual growth of 10%. So, even though trademark filing activity is growing in the US, it is expanding faster in India, and the gap between the two in terms of overall volume is likely to close in 2025 or 2026, he added. Drug company Alkem Labs led local companies with 4,931 trademark registrations as of Jan 1, 2025, followed by ITC (4,923). The growth in India has been driven by a strong domestic brand sector, which accounts for over 95% of trademark applications filed annually in India, the latest Trademark Filing Trends 2025 report said. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Yahoo
14-05-2025
- Business
- Yahoo
Clarivate Enhances OFF-X with Pathway Maps to Accelerate Target Safety Assessments
R&D teams can streamline safety evaluations, reduce risks and enable faster decision-making in drug development using new visual and data-driven insights LONDON, May 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the incorporation of Pathway Maps in OFF-X, a cutting-edge translational safety intelligence solution. With over 30% of drug development failures attributed to safety issues1, preclinical and translational research teams face increasing pressure to identify potential liabilities earlier in the target selection process. Pathway Maps provide powerful visual tools that offer deeper insights into the biological mechanisms underlying diseases and target interactions, streamlining target safety assessments and enabling faster, data-driven decisions. Traditional safety data collection is often fragmented and time-consuming, creating delays in critical go/no-go decisions. With the addition of Pathway Maps to OFF-X, researchers can now explore disease-specific visualizations of key signaling pathways and molecular processes—uniquely overlaid with curated, multi-source safety data. This integration enables users to quickly pinpoint potential safety liabilities across upstream or downstream targets, adding biological context to risk assessment. By bringing together visual disease biology and comprehensive safety intelligence in one platform, OFF-X addresses a critical industry gap—empowering teams to make faster, more confident decisions across the drug development lifecycle. Anne Lecocq, SVP and GM, R&D, Life Sciences & Healthcare, Clarivate, said: "The ability to assess the safety of drug targets early in development is a critical factor in reducing costly late-stage failures and accelerating time to market. At Clarivate, we're committed to empowering our customers with tools that not only streamline their workflows but also provide deeper, more actionable insights that improve patient lives and create a healthier tomorrow. The introduction of Pathway Maps into OFF-X is a game-changer—it integrates complex biological data with curated safety intelligence, helping researchers make confident, data-driven decisions faster and with greater accuracy." With this release, OFF-X reaffirms its unique position as a platform that integrates proprietary physiological and disease pathway visualizations with curated safety data from diverse sources. This integration streamlines data access and enhances risk evaluation, providing researchers with the confidence to make more informed decisions and refine mitigation strategies. Designed to support researchers throughout the drug development lifecycle—from early discovery to post-marketing surveillance— OFF-X offers a unified resource for translational safety intelligence. In the drug discovery and preclinical space, the combination OFF-X and Cortellis Drug Discovery Intelligence provides the most powerful approach for researchers to cover both efficacy and safety. For more information on how OFF-X helps optimize target safety assessments, visit here. About ClarivateClarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit 1 Source: Guengerich FP. Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab Pharmacokinet. 2011;26(1):3-14. doi: 10.2133/ Epub October 22, 2010. PMID: 20978361; PMCID: PMC4707670. Media Contact: Catherine DanielDirector, External Communications, Life Sciences & HealthcareClarivatenewsroom@ View original content to download multimedia: SOURCE Clarivate Plc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
